RBC Capital initiated coverage of United Therapeutics (UTHR) with an Outperform rating and $569 price target The firm views the company as a leader in rare lung diseases with a $2B blockbuster franchise in Tyvaso. United Therapeutics has a “resilient” base business and “multiple pipeline shots on goal,” the analyst tells investors in a research note. RBC’s conversations with five key onion leaders and survey of 36 pulmonologists leave it bullish on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics management to meet with Cantor Fitzgerald
- United Therapeutics price target raised to $525 from $405 at Cantor Fitzgerald
- United Therapeutics price target raised to $575 from $510 at Oppenheimer
- United Therapeutics price target raised to $500 from $400 at H.C. Wainwright
- United Therapeutics price target raised to $560 from $415 at UBS